Latest Conference Articles

In this analysis, investigators found consistent benefits over placebo among children with type 2 asthma treated with dupilumab, regardless of condition length.

At 2025 New Wave Dermatology, HCPLive spoke with Miranti on treating the 4 pillars of pathogenesis, including sebum production, inflammation, and more.

In this ATS 2025 interview, Arthur Reingold, MD, was asked about the effects of the COVID-19 pandemic on immunization rates as well as pulmonologists’ role.

These data from ATS 2025 point to climate change as a potential influence on the burden associated with obstructive sleep apnea (OSA).

Pande explains findings from his research on immunosuppression in interstitial lung disease suggesting this treatment does not affect fibrosis progression.

Over 60% of patients admitted to the ICU with ARF experienced some degree of sleep disturbance after admission.

In this interview at ATS 2025, Reingold highlighted his presentation on the global immunization divide and overcoming barriers to universal vaccine coverage.

These data, presented at ATS 2025, highlight the efficacy results of methotrexate when compared to prednisone for pulmonary sarcoidosis.

New research sheds light on improved waitlist outcomes after new allocation guidelines for lung transplants prioritizing medical urgency were implemented.

Zirwas shares top dermatology studies, highlights AD misdiagnosis, and reveals how pollution and fabrics may trigger adult-onset atopic dermatitis.

Williams discusses the complicated relationship between ophthalmologists and their work as well as the benefits and challenges of reaching out to underrepresented groups.

Zirwas outlines a 4-visit approach to diagnosing spongiotic dermatitis, helping dermatologists manage uncertain rashes more effectively.

At New Wave Derm 2025, Kalil shared expert tips on evaluating and diagnosing scarring vs non-scarring hair loss using clinical tools.

Children with KCN have greater risk of progression than adults; study findings suggest CXL may slow that progression or prevent it altogether.

Kalil discusses the latest advancements in hair loss treatments, including innovative therapies and ongoing research in dermatology for effective solutions.

Guan describes the potential value of using wearable devices to enhance IBS management by tracking sleep and exercise.

The Amsterdam-Oxford Model successfully predicted adverse outcomes in a US cohort of PSC patients, validating its generalizability.

Goldberg’s post hoc analysis has indicated that AREDS and AREDS2 vitamins do not slow either GA progression to the fovea or overall GA growth.

Anthony Lembo, MD, explains the Vibrating Capsule’s utility in chronic idiopathic constipation and reviews findings from a post hoc analysis of a phase 3 trial.

A post-hoc analysis has indicated that aflibercept 8 mg has the potential to shorten or lengthen intervals between treatment in patients with DME.

View slated interviews with experts and 7 clinical trials to watch at ATS 2025.

Leffler describes progress made in the understanding of celiac disease but points to continued challenges in diagnosis and management.

Jeemin Kwon, MD, describes the role GI symptom-related anxiety plays in shaping dietary patterns and altering the gut microbiome in patients with IBS.

An analysis of several datasets cataloguing the switch revealed that dosing can be extended up to 2 weeks for patients with nAMD who received prior anti-VEGF therapy.

The recent trial indicates that the oral treatment gildeuretinol reduces GA lesion growth rates, as well as achieving better BCVA scores.

A pair of experts discuss their research on trends in the use of GLP-1 RAs in patients with IBD as well as their safety and efficacy in this patient population.

Ixo-vec, a potential one shot therapy for age-related macular degeneration has achieved noninferior results in maintaining best-corrected visual acuity and central subfield thickness.

Findings suggest sleep disorders are common in PBC and are linked to worse biochemical markers, greater symptom burden, and reduced treatment response rates.